MOCS2 and Alzheimer disease: The study by Janna et al[23] reported that the transcriptome expression levels of CETN3 (Centrin 3) and MOCS2 (Molybdenum Cofactor Synthesis 2) in AD patients were significantly lower compared to those in the normal control group, findings that align with our own research.